These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 15633133

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J.
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
    Grander W, Eller P, Fuschelberger R, Tilg H.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
    [Abstract] [Full Text] [Related]

  • 5. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
    Hinterhuber L, Graziadei IW, Kähler CM, Jaschke W, Vogel W.
    Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
    [Abstract] [Full Text] [Related]

  • 6. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
    Molnar C, Alber H, Colleselli D, Vogel W, Kähler CM.
    Wien Klin Wochenschr; 2004 Sep 30; 116(17-18):627-30. PubMed ID: 15515882
    [Abstract] [Full Text] [Related]

  • 7. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
    Sağ S, Yeşilbursa D, Güllülü S.
    Turk J Gastroenterol; 2014 Aug 30; 25(4):429-32. PubMed ID: 25254528
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G, von Hunnius P.
    Eur J Clin Invest; 2006 Sep 30; 36 Suppl 3():62-6. PubMed ID: 16919013
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
    Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G.
    Wien Med Wochenschr; 2005 Aug 30; 155(15-16):376-80. PubMed ID: 16160926
    [Abstract] [Full Text] [Related]

  • 11. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
    Hino T, Hayashida A, Okahashi N, Wada N, Watanabe N, Obase K, Neishi Y, Kawamoto T, Okura H, Yoshida K.
    Intern Med; 2009 Aug 30; 48(8):597-600. PubMed ID: 19367055
    [Abstract] [Full Text] [Related]

  • 12. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
    Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, Clozel M, Lebrec D.
    Hepatology; 1998 Sep 30; 28(3):655-9. PubMed ID: 9731554
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
    Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod LP.
    Eur J Gastroenterol Hepatol; 2006 Oct 30; 18(10):1117-9. PubMed ID: 16957519
    [Abstract] [Full Text] [Related]

  • 15. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
    Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, Davis GL.
    Am J Transplant; 2007 May 30; 7(5):1258-64. PubMed ID: 17286619
    [Abstract] [Full Text] [Related]

  • 16. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
    Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH.
    Transplantation; 2004 Jun 15; 77(11):1775-6. PubMed ID: 15201684
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ, Roux S.
    Expert Opin Investig Drugs; 2002 Jul 15; 11(7):991-1002. PubMed ID: 12084009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.